| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | 0.022 | 0.9 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |